CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Arcadia Biosciences Q3 revenue rises 24% to record high

By Reuters News


Overview

  • Wellness products maker's Q3 revenue rose 24% yr/yr, highest ever for Zola brand

  • Net income attributable to common stockholders more than doubled from prior year

  • Growth driven by strong summer programs and new distribution opportunities


Outlook

  • Arcadia to begin shipping new 1L espresso formulation this month

  • Company plans to launch slim cans for Zola products in early 2027

  • Arcadia sees new distribution opportunities in 2027, including in Texas


Result Drivers

  • SUMMER PROGRAMS - Co said strong volumes from summer programs drove Q3 revenue growth

  • TARIFF REFUND - Cost of revenues decreased due to a tariff refund of about $175,000 in July 2026

  • WARRANT AND OPTION GAINS - Net income improvement was mainly due to a $2.6 mln gain related to the change in estimated fair value of common stock warrant and option liabilities


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$1.62 mln

Q3 EPS

$0.29

Q3 Net Income

$1.76 mln

Q3 Operating Expenses

$2.46 mln


Reuters Recommended Reads

  • Nov 10 - Jones Soda Q3 revenue jumps 204% as distribution expands; gross margin expands

  • Nov 10 - B&G Foods Q3 sales beat estimates on acquisitions, volume growth

  • Nov 10 - GEN Restaurant Group Q3 revenue falls 3% on lower restaurant sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.